© 2019 Ceres Nanosciences, Inc. All Rights Reserved


Clinical Study Program

Your patients could be eligible for a new clinical study program 
Ceres Nanosciences is seeking urine samples from patients presenting with new acute Lyme infections

To qualify for this study, a patient must have clear and documented clinical diagnosis of a new/acute Lyme infection [1], including exposure to Lyme and clinical symptoms like fever, chills, headache, fatigue, muscle and joint aches, and swollen lymph nodes, and/or EM rash

[1] See: CDC’s “Early Signs and Symptoms (3 to 30 days after tick bite).”

Patients who qualify for the study will not be billed for the Nanotrap® Lyme Antigen Lab Developed Test and will receive the benefit of test results at initial visit and at follow up visit. 

Participants must provide at least 150-200 mL urine (2 urine cups) from each patient at two time points (day of visit to physician and 30 days later).


Samples most be stored in refrigeration and shipped to Ceres’ CAP/CLIA lab in Virginia. Ceres will coordinate shipping with office. 

Patient participants should receive standard of care 2-tiered serology test at two time points (day of visit to physician and 30 days later) and testing should be performed per current standard of care via third party reference lab, e.g. LabCorp, Quest Diagnostics

If you see patients with new cases of acute Lyme, and would like to offer this opportunity to your patients, please inquire at info@ceresnano.com